Ancer-20 (Z-100) / Zeria Pharma - LARVOL DELTA

Potential of Z-100, extracted from Mycobacterium tuberculosis strain Aoyama B, as a hot tumor inducer. (PubMed, Cancer Cell Int) - "Furthermore, the antitumor effects of Z-100 were abolished in mice treated with an anti-CD8 antibody and in IL-12p40 KO mice. Thus, Z-100 induces its antitumor effects by increasing tumor-infiltrating CD8 T cells, suggesting that Z-100 may be a useful cancer therapy by acting as a hot tumor inducer."

Journal • Infectious Disease • Oncology • Oral Cancer • Pulmonary Disease • Respiratory Diseases • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Tuberculosis

Peptidoglycan-Like Components in Z-100, Extracted from Mycobacterium tuberculosis Strain Aoyama B, Increase IL-12p40 via NOD2. (PubMed, J Immunol Res) - "Further, subcutaneous administration of Z-100 to mice significantly elevated expression of IL-12p40 and IL-1β and showed a trend towards increasing TNF-α in the skin. Z-100 induced the production of immunomodulatory cytokines from various types of macrophages and specifically increased IL-12p40 production through peptidoglycan-like components via NOD2."

Journal • Immune Modulation • Infectious Disease • Inflammation • Pulmonary Disease • Respiratory Diseases • Tuberculosis • CD14 • IL1B • NLRC5 • TNFA

Trial to Optimally Show the Pharmacological Action of Z-100 (clinicaltrials.gov) - P3 | N=72 | Completed | Sponsor: Zeria Pharmaceutical | Active, not recruiting ➔ Completed | Trial completion date: Oct 2022 ➔ Dec 2021

Trial completion • Trial completion date • Cervical Cancer • Oncology • Solid Tumor

Randomized Study of Z-100 Plus Radiation Therapy to Treat Cervical Cancer (clinicaltrials.gov) - P3 | N=793 | Completed | Sponsor: Zeria Pharmaceutical | Active, not recruiting ➔ Completed | Trial primary completion date: Oct 2021 ➔ Jun 2021

Trial completion • Trial primary completion date • Cervical Cancer • Oncology • Solid Tumor

Trial to Optimally Show the Pharmacological Action of Z-100 (clinicaltrials.gov) - P3; N=70; Recruiting; Sponsor: Zeria Pharmaceutical; Not yet recruiting ➔ Recruiting

Enrollment open • Biosimilar • Gynecologic Cancers • Oncology • Solid Tumor

Trial to Optimally Show the Pharmacological Action of Z-100 (clinicaltrials.gov) - P3; N=72; Active, not recruiting; Sponsor: Zeria Pharmaceutical; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed

Randomized Study of Z-100 Plus Radiation Therapy to Treat Cervical Cancer (clinicaltrials.gov) - P3; N=780; Active, not recruiting; Sponsor: Zeria Pharmaceutical; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed